Global Idiopathic Pulmonary Fibrosis Market Review 2016-2019 and $5.7+ Billion Industry Forecast to 2026 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 20, 2019--
The “Global Idiopathic Pulmonary Fibrosis Market Analysis 2019” report has been added to ResearchAndMarkets.com’s offering.
The Idiopathic Pulmonary Fibrosis market is expected to reach $5,733.24 million by 2026 growing at a CAGR of 13.5% from 2018 to 2026.
Factors such as the rise in geriatric population, a surge in cigarette smoking population and an increase in a number of patients suffering from idiopathic pulmonary fibrosis are fuelling the market growth. However, unavailability of proper treatment options is restricting the market growth.
Based on the route of administration, the parenteral route segment is to be the most preferred route of drug administration during the forecast period. Drugs administered by the parenteral route bypass the first-pass metabolism and enter the bloodstream directly. This helps in the fast delivery of drugs or nutrients into the body.
The key vendors mentioned are Biogen, Boehringer Ingelheim, MediciNova, Inc., Afferent Pharmaceuticals, Baxter, Bristol-Myers Squibb, F. Hoffmann-La Roche, Promedior, Prometheus Laboratories, Amgen, FibroGen, Merck, Prometic Life Sciences, Galapagos, Cipla Inc., Asahi Kasei Corporation, and Sanofi S.A.
Key Questions Answered in this Report
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
- Fastest growing markets analysed during the forecast period
Key Topics Covered
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Idiopathic Pulmonary Fibrosis Market, By Type
5.2 Antifibrotic Agents
5.3 Systemic Corticosteroids
5.4 Immunosuppressant Drugs
5.5 Tyrosine Kinase Inhibitors
6 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type
7 Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration
8 Global Idiopathic Pulmonary Fibrosis Market, By Application
8.4 Other Applications
9 Global Idiopathic Pulmonary Fibrosis Market, By End User
9.3 Academic and Research Organizations
9.5 Ambulatory Surgical Centers
9.6 Other End Users
10 Global Idiopathic Pulmonary Fibrosis Market, By Geography
10.2 North America
10.4 Asia Pacific
10.5 South America
10.6 Middle East & Africa
11 Strategic Benchmarking
12 Vendors Landscape
12.2 Boehringer Ingelheim
12.3 MediciNova Inc.
12.4 Afferent Pharmaceuticals
12.6 Bristol-Myers Squibb
12.7 F. Hoffmann-La Roche
12.9 Prometheus Laboratories
12.13 Prometic Life Sciences
12.15 Cipla Inc.
12.16 Asahi Kasei Corporation
12.17 Sanofi S.A.
For more information about this report visit https://www.researchandmarkets.com/r/f10g4g
View source version on businesswire.com:https://www.businesswire.com/news/home/20191120005839/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 11/20/2019 01:49 PM/DISC: 11/20/2019 01:49 PM